Clinical impact of PET/MRI in oligometastatic colorectal cancer
Felipe Furtado(Harvard University), Onofrio A. Catalano(Harvard University), Robin Striar(Harvard University), Rocco Ricciardi(Massachusetts General Hospital), Márk Vangel(Massachusetts General Hospital), Mark Anderson(Great North Children's Hospital), David Groshar(Tel Aviv University), Theodore S. Hong(Massachusetts General Hospital), Liliana Bordeianou(Massachusetts General Hospital), Lale Umutlu(Essen University Hospital), James C. Cusack(Massachusetts General Hospital), Cristina R. Ferrone(Cedars-Sinai Medical Center), Jennifer Y. Wo(Massachusetts General Hospital), Amirkasra Mojtahed(Harvard University), Krista Suarez-Weiss(Brigham and Women's Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Heike E. Daldrup‐Link(Lucile Packard Children's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Motaz Qadan(Massachusetts General Hospital)
Cited by 27
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k